<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>MPS/NGS tests</title>
<link rel="stylesheet" type="text/css" href="view.css" media="all">
<script type="text/javascript" src="view.js"></script>
<style>
.collapsible {
  background-color: #ebfafa;
  color: black;
  cursor: pointer;
  padding: 8px;
  width: 100%;
  border: none;
  text-align: left;
  outline: none;
  font-size: 14px;
}

.active, .collapsible:hover {
  background-color: #fff2e6;
}

.content {
  padding: 0 18px;
  max-height: 0;
  overflow: hidden;
  transition: max-height 0.2s ease-out;
  background-color: #f1f1f1;
}
</style>
</head>
<body>


<div>

<img id="top" src="top.png" alt="">
<div id="form_container">
	<div class="form_description">
		<h2 align="center">
					Massive Parallel Sequencing (Next Generation Sequencing)
		</h2>
	</div>
<p align="center">
<img src="data:image/png;base64,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">
<img src="data:image/png;base64,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">
<img src="data:image/png;base64,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">
<img src="data:image/png;base64,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">
<img src="data:image/png;base64,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">
<img src="data:image/png;base64,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">
</p>

<button class="collapsible">Tumor Content</button>
<div class="content">
<p>
<a href=".\cap\A start at standardizing neoplastic cellularity assessment-CAPTODAY.pdf" target="_blank">CAP</a> recommends using <a href=".\cap\Neoplastic_Fig5.jpg" target="_blank">neoplastic cellularity</a> as the number of neoplastic cells or nuclei compared to the overall or toal number of cells or nuclei.<br>
</p>
</div>

<button class="collapsible">Illumina MPS (NGS) </button>
<div class="content">
<p>Massive Parallel Squencing (Next Generation Sequencing) is ran on the Illumina iSeq 100, MiniSeq and NextSeq 500, using "sequencing by synthesis" chemistry, upon different targeted sequencing panels.</p>
<p>
Genomic DNA QC : Quantified by Qubit and the integrity control by conventional PCR<br>
Library QC    : Check by automatic electrophoresis (Bioanalyser)<br>
Sequencing QC : Coverage > 500x, Q30 > 80%<br>
<br>
Bioinformatics :<br>
                Illumina Local Run Manager on a desktop PC <a href="https://support.illumina.com/help/BaseSpace_App_DNA_Amplicon_v2_OLH_1000000041403/Content/Source/HomePages/Home_Page_DNA_Amplicon_App.htm" target="_blank">
		DNA Amplicon (BaseSpace Workflow) 2.1.0.19 </a> [DNA Amplicon Workflow (3.24.1.8+
                master), BWA-MEM Whole-Genome(Aligner)0.7.9a-isis-1.0.2, Pisces
                Variant Caller 5.2.9.23, Illumina Annotation Engine 2.0.11-0-
                g7fb24a09, Bam Metrics v0.0.22, and SAMtools 0.1.19-isis-1.0.3, 
				Annotation Dataset 91.26.44] 
 <br><br>
<img src=".\cap\Workflow_appDNAA_576x507.png" alt="workflow" width="600">
<br>
Curation      : <br>
Human GRCh37/hg19, ClinVar, Genome Nexus, Franklin, VarSome<br>
<br>
<br>
Limitations   : The workflow could detect SNV-indel type  mutations with a variant allelic frequency greater or equal to 5%. However, variants with VAF<10% might fall short of Sanger sequencing confirmation. Due to the nature of FFPE specimen and limitations of the amplicon-based library preparation, genomic changes leading to false negativity, including, but not limited to, large deletion, large duplication and gross chromosomal abnormalities, cannot be completely excluded.

</p>
</div>

<button class="collapsible">Ion Torrent MPS (NGS) </button>
<div class="content">
<p>The <a href="https://www.thermofisher.com/hk/en/home/life-science/sequencing/next-generation-sequencing/ion-torrent-next-generation-sequencing-workflow/ion-torrent-next-generation-sequencing-run-sequence/ion-torrent-genexus-system.html" target="_blank">Ion Torrent Genexus System</a> automates sample and library preparation, sequencing, analysis, and reporting. The Genexus Purification System and Genexus Integrated Sequencer with Genexus Software work together seamlessly, tracking sample information and results automatically through the process. This automated system reduces manual steps and facilitates quality data and quick reports.</p>
<p>
Genomic DNA/RNA QC : Quantified by Qubit and the integrity control by conventional PCR<br>
Library QC    : Integrated in the automated system<br>
DNA Sequencing QC : >=Q20 bases, Uniformity<br>
RNA Sequencing QC : >=Q20 bases, Mapped<br>
<br>
Bioinformatics : Integrated<br>
The factory bioinformatics reports a standardized table of known variants. An in-house bioinformatic pipeline is installed for screening uncalled variants for the 12-gene lung cancer panel. Sequencing data of selected cases should also be reviewed by Integrated Genome Viewer (IGV).<br><br>
Curation      : <br>
Human GRCh37/hg19, ClinVar, Genome Nexus, Franklin, VarSome<br>
<br>
<br>
Limitations   : The workflow could detect SNV-indel type mutations with a variant allelic frequency greater or equal to 5%. However, variants with VAF less than 10% might fall short of Sanger sequencing confirmation. Due to the nature of FFPE specimen and limitations of the amplicon-based library preparation, false negative results cannot be completely excluded. These latter missed genomic changes might include large deletion, large duplication, gross chromosomal abnormalities, intronic variants, etc. 

</p>
</div>

<p align="center">
<img src="data:image/png;base64,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"/>
</p>

<button class="collapsible">BRCA1 and BRCA2 Somatic and Germline Testing (tumor tissue and blood)</button>
<div class="content">
<p>
Somatic mutation testing is done on the FFPE block or cytology cell block. <br><br>
Germline mutation testing is performed on FFPE block and peripheral white cells from the EDTA blood sample, and is also supplemented by MLPA.
</p>

<p>
Sequencing	  :	The AmpliSeq for Illumina BRCA Panel is a targeted resequencing 
				assay for somatic and germline variants across BRCA1 and BRCA2 genes, 
				targeting all the coding exonic regions and the flanking intronic sequences 
				of the BRCA1 and BRCA2 genes.
</p>
<p>
<a href=".\cap\MLPA_General_Protocol_MDP-v007.pdf" target="_blank">MLPA</a>          : SALSA MLPA Probemix kits (MRC, Holland):
                <a href=".\cap\Product_description_P002-D1_BRCA1-v08.pdf" target="_blank">P002 BRCA1</a>,
				<a href=".\cap\Product_description_P239-C1_BRCA1_region-v02.pdf" target="_blank">P090 BRCA2</a> and 
				<a href=".\cap\Product_description_P090-C1_BRCA2-v03.pdf" target="_blank">P239 BRCA1 region</a>;<br>
				confirmed by 
				<a href=".\cap\Product_description_P087-D1_BRCA1_Confirmation-v05.pdf"  target="_blank">P087 BRCA1 Confirmation</a> or
				<a href=".\cap\Product_description_P077-B1_BRCA2_Confirmation-v06.pdf"  target="_blank">P077 BRCA2 Confirmation</a> whichever is applicable;				
                <a href=".\cap\Coffalyser.Net-Reference-Manual-v07.pdf" target="_blank">Coffalyzer.Net software</a> v.220513.1739 (database v.220401.0000) for <a href=".\cap\MLPA_QC_LKCHAN.pdf"  target="_blank">quality control</a>, visualization and analysis of data.

</p>
<p>
All findings are to be confirmed by orthogonal methods, including Sanger sequencing, RT-PCR and FISH.
</p>
<p>
Consent is necessary for ordering this test (either somatic test alone, or somatic and germline tests). (<a href=".\cap\BRCA12Consent-e01.docx">Engish</a>) (<a href=".\cap\BRCA12Consent-c01.docx">Chinese</a>)
</p>
<p>
Pamphlets for BRCA testing in high staged, high grade ovarian cancer (<a href=".\cap\BRCA12Leaflet-e01.pdf" target="_blank">English</a>)(<a href=".\cap\BRCA12Leaflet-c01.pdf" target="_blank">Chinese</a>)
</p>
</div>

<button class="collapsible">Lung Cancer Somatic Mutation Analysis (tumor tissue) [coming soon]</button>
<div class="content">
<p>
The Oncomine Precision Assay, Ion Torrent Genexus System, is an automatic targeted assay for genetic analysis of 50 genes with known relevance to solid tumors. Variants can be confirmed by orthogonal methods (PCR-Sanger sequencing, RT-PCR + Sanger, FISH, etc.). SNV/indel, CNV and fusion variants are included.
</p>
<p>
Actionable variants in a 12-gene lung cancer somatic mutation panel are reported:<br>
ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK1, NTRK2, NTRK3, PIK3CA, RET and ROS1 genes<br>
</p>
<p>
Hot spot mutations (45):<br>
           AKT1   AKT2  AKT3  ALK   AR    ARAF  BRAF  CDK4   CDKN2A  CHEK2 CTNNB1 EGFR  ERBB2 ERBB3 ERBB4 ESR1  FGFR1 FGFR2  FGFR3   FGFR4 FLT3   GNA11 GNAQ  GNAS  HRAS  IDH1  IDH2  KIT    KRAS    MAP2K1 MAP2K2 MET   MTOR  NRAS  NTRK1 NTRK2 NTRK3 PDGFRA PIK3CA  PTEN RAF1   RET   ROS1  SMO   TP53<br>
</p>

<p>
Copy Number Variants (14):<br>
           ALK  AR  CD274  CDKN2A EGFR ERBB2 ERBB3 FGFR1 FGFR2 FGFR3 KRAS MET PIK3CA PTEN<br>
</p>

<p>
Fusion Drivers (18):<br>
           ALK   AR    BRAF  EGFR  ESR1 FGFR1 FGFR2 FGFR3 MET NRG1 NTRK1 NTRK2 NTRK3 NUTM1 RET  ROS1  RSPO2 RSPO3<br>

<br>
</p>
</div>

<button class="collapsible">Lung Cancer Somatic Mutation Analysis (tumor tissue) [backup]</button>
<div class="content">
<p>
The AmpliSeq for Illumina Focus Panel is a targeted resequencing assay for biomarker analysis of 52 genes with known relevance to solid tumors. Variants can be confirmed by orthogonal methods (PCR-Sanger sequencing, RT-PCR + Sanger, FISH, etc.). SNV/indel and fusion variants are reported. Detection of CNV variant required cloud computation and is performed infrequently.
</p>
<p>
Actionable variants in a 12-gene lung cancer somatic mutation panel are reported:<br>
ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK1, NTRK2, NTRK3, PIK3CA, RET and ROS1 genes<br>
</p>
<p>
Hot spot mutations (35):<br>
AKT1, ALK, AR,	BRAF,	CDK4,	CTNNB1,	DDR2,	EGFR,	ERBB2,	ERBB3,	ERBB4,	ESR1, FGFR1, FGFR2, FGFR3,	GNA11,	GNAQ,	HRAS,	IDH1,	IDH2,	JAK1,	JAK2,	JAK3,	KIT,	KRAS,	MAP2K1,	MAP2K2,	MET,	MTOR,	NRAS,	PDGFRA,	PIK3CA,	RAF1,	RET,	ROS1,	SMO
</p>

<p>
Copy Number Variants (19):<br>
ALK,	AR,	BRAF,	CCND1,	CDK4,	CDK6,	EGFR,	ERBB2,	FGFR1,	FGFR2,	FGFR3,	FGFR4,	KIT,	KRAS,	MET,	MYC,	MYCN,	PDGFRA,	PIK3CA
</p>

<p>
Fusion Drivers (23):<br>
	ABL1,	ALK,	AKT3,	AXL,	BRAF,	EGFR,	ERBB2,	ERG,	ETV1,	ETV4,	ETV5,	FGFR1,	FGFR2,	FGFR3,	MET,	NTRK1,	NTRK2,	NTRK3,	PDGFRA,	PPARG,	RAF1,	RET,	ROS1
<br>
<br>
<img src=".\cap\AmpliSeq_for_Illumina_Focus_Fusion_List.png" alt="Fusion list">
</p>
</div>

<button class="collapsible">Comprehensive Panel for Solild Tumor (somatic DNA + RNA)  [not launching]</button>
<div class="content">
<p>
The AmpliSeq for Illumina Comprehensive Panel v3 offers coverage of key cancer genes, including kinase domains and genes involved in DNA repair, targetting 161 unique cancer-associated genes
</p>
<p>
Hot spot mutations:<br>
AKT1, AKT2, AKT3, ALK, AR, ARAF, AXL, BRAF, BTK, CBL, CCND1, CDK4, CDK6, CHEK2, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ERCC2, ESR1, EZH2, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, H3F3A, HIST1H3B, HNF1A, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KDR, KIT, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAP2K4, MAPK1, MAX, MDM4, MED12, MET, MTOR, MYC, MYCN, MYD88, NFE2L2, NRAS, NTRK1, NTRK2, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPP2R1A, PTPN11, RAC1, RAF1, RET, RHEB, RHOA, ROS1, SF3B1, SMAD4, SMO, SPOP, SRC, STAT3, TERT, TOP1, U2AF1, XPO1<br>
</p>
<p>
Full-length genes:<br>
ARID1A, ATM, ATR, ATRX, BAP1, BRCA1, BRCA2, CDK12, CDKN1B, CDKN2A, CDKN2B, CHEK1, CREBBP, FANCA, FANCD2, FANCI, FBXW7, MLH1, MRE11A, MSH2, MSH6, NBN, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, PALB2, PIK3R1, PMS2, POLE, PTCH1, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RB1, RNF43, SETD2, SLX4, SMARCA4, SMARCB1, STK11, TP53, TSC1, TSC2<br>
</p>
<p>
Copy number variants:<br>
AKT1, AKT2, AKT3, ALK, AR, AXL, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, CDKN2A, CDKN2B, EGFR, ERBB2, ESR1, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, IGF1R, KIT, KRAS, MDM2, MDM4, MET, MYC, MYCL, MYCN, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPARG, RICTOR, TERT, TSC1, TSC2<br>
</p>
<p>
Fusion drivers:<br>
AKT2, ALK, AR, AXL, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, ERBB4, ERG, ESR1, ETV1, ETV4, ETV5, FGFR1, FGFR2, FGFR3, FGR, FLT3, JAK2, KRAS, MDM4, MET, MYB, MYBL1, NF1, NOTCH1, NOTCH4, NRG1, NTRK1, NTRK2, NTRK3, NUTM1, PDGFRA, PDGFRB, PIK3CA, PPARG, PRKACA, PRKACB, PTEN, RAD51B, RAF1, RB1, RELA, RET, ROS1, RSPO2, RSPO3, TERT<br>
</p>
</div>
<script>
var coll = document.getElementsByClassName("collapsible");
var i;

for (i = 0; i < coll.length; i++) {
  coll[i].addEventListener("click", function() {
    this.classList.toggle("active");
    var content = this.nextElementSibling;
    if (content.style.maxHeight){
      content.style.maxHeight = null;
    } else {
      content.style.maxHeight = content.scrollHeight + "px";
    } 
  });
}
</script>
 
<br>
<div id = "footer">
Last upated on 10-Jun-2023.<br><br>
The html form and cascade style sheet were created on <a href="https://www.phpform.org" target="_blank">pForm</a>,<br>
with references to Javascripts and codes published in <a href="https://www.w3schools.com/" target="_blank">W3 School</a> and <a href="https://stackoverflow.com/" target="_blank">StackOverflow</a><br>
and image modified from <a href="https://icons8.com" target="_blank">Icons8</a>.
<br>
<br>
<br>
Anatomical Pathology Division, Queen Mary Hospital, Hong Kong.
</div>
</div>
<img id="bottom" src="bottom.png" alt="">
</div>


</body>
</html>
